135 related articles for article (PubMed ID: 31910387)
1. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy.
Palumbo C; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
J Natl Compr Canc Netw; 2020 Jan; 18(1):44-51. PubMed ID: 31910387
[TBL] [Abstract][Full Text] [Related]
2. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder.
Palumbo C; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Shariat SF; Saad F; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Urol Oncol; 2019 Dec; 37(12):893-899. PubMed ID: 31296422
[TBL] [Abstract][Full Text] [Related]
3. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.
Bianchi M; Becker A; Hansen J; Trinh QD; Tian Z; Abdollah F; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI; Sun M
BJU Int; 2013 Jun; 111(8):E283-9. PubMed ID: 23714646
[TBL] [Abstract][Full Text] [Related]
4. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
5. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.
Nocera L; Collà Ruvolo C; Stolzenbach LF; Wenzel M; Tian Z; Larcher A; Capitanio U; Mirone V; Tilki D; Chun FKH; Kapoor A; Shariat SF; Saad F; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):182-190. PubMed ID: 33653677
[TBL] [Abstract][Full Text] [Related]
6. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
7. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma.
Tallman JE; Pearce SM; Kuchta K; Helfand BT; Eggener SE
J Urol; 2017 Nov; 198(5):1027-1032. PubMed ID: 28551443
[TBL] [Abstract][Full Text] [Related]
8. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
[TBL] [Abstract][Full Text] [Related]
10. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer.
Pecoraro A; Palumbo C; Knipper S; Mistretta FA; Tian Z; Shariat SF; Saad F; Briganti A; Fiori C; Porpiglia F; Karakiewicz PI
J Urol; 2019 Dec; 202(6):1120-1126. PubMed ID: 31347950
[TBL] [Abstract][Full Text] [Related]
11. Conditional cancer-specific survival after radical hepatectomy in patients with nonmetastatic intrahepatic cholangiocarcinoma.
Yan X; Wang L; Meng Z
Scand J Gastroenterol; 2022 Apr; 57(4):481-485. PubMed ID: 35007461
[TBL] [Abstract][Full Text] [Related]
12. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
[TBL] [Abstract][Full Text] [Related]
13. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT
Marchioni M; Bandini M; Pompe RS; Martel T; Tian Z; Shariat SF; Kapoor A; Cindolo L; Briganti A; Schips L; Capitanio U; Karakiewicz PI
BJU Int; 2018 Mar; 121(3):383-392. PubMed ID: 28940649
[TBL] [Abstract][Full Text] [Related]
14. The key role of time in predicting progression-free survival in patients with renal cell carcinoma treated with partial or radical nephrectomy: conditional survival analysis.
Abdollah F; Suardi N; Capitanio U; Matloob R; Fossati N; Castiglione F; Di Trapani E; Di Trapani D; Russo A; Carenzi C; Montorsi F; Rigatti P; Bertini R
Urol Oncol; 2014 Jan; 32(1):43.e9-16. PubMed ID: 23911684
[TBL] [Abstract][Full Text] [Related]
15. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
16. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy.
Bandini M; Smith A; Zaffuto E; Pompe RS; Marchioni M; Capitanio U; Chun FK; Kapoor AB; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):51-57. PubMed ID: 29022072
[TBL] [Abstract][Full Text] [Related]
17. Nodal involvement at nephrectomy is associated with worse survival: a stage-for-stage and grade-for-grade analysis.
Sun M; Bianchi M; Hansen J; Abdollah F; Trinh QD; Lughezzani G; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
Int J Urol; 2013 Apr; 20(4):372-80. PubMed ID: 23039208
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis.
Becker A; Hickmann D; Hansen J; Meyer C; Rink M; Schmid M; Eichelberg C; Strini K; Chromecki T; Jesche J; Regier M; Randazzo M; Tilki D; Ahyai S; Dahlem R; Fisch M; Zigeuner R; Chun FK
Eur J Surg Oncol; 2016 Mar; 42(3):419-25. PubMed ID: 26520403
[TBL] [Abstract][Full Text] [Related]
19. Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients.
Meskawi M; Sun M; Ismail S; Bianchi M; Hansen J; Tian Z; Hanna N; Trinh QD; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
Mod Pathol; 2013 Aug; 26(8):1144-9. PubMed ID: 23370773
[TBL] [Abstract][Full Text] [Related]
20. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
